Clinical efficacy, saftey and pharmacodynamics of antifungal agents on chronic pulmonary mycosis

Clinical efficacy, saftey and pharmacodynamics of antifungal agents on chronic pulmonary mycosis - Clinical efficacy and of antifungal agents on pulmonary mycosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003108

Enrollment

Registered

2010-01-27

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic pulmonary diseases chronic pulmonary mycosis

Interventions

Liposomal Amphotericin B Itraconazole

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hospitalized patients with chronic pulmonary mycosis 2) Patients with chronic respiratory diseases

Exclusion criteria

Exclusion criteria: 1) Patients under treatment of radiotherapy and immunosuppressant at present 2) Patients who have serious acute diseases obviously

Design outcomes

Primary

Measure	Time frame
clnical efficacy and safety of the antifungal agents on chnoric pulmonary mycosis	—

Secondary

Measure	Time frame
Serum and sputum concentrations of antifungal agents	—

Countries

Japan

Contacts

Public ContactShinji Teramoto

National Hospital Organization, Tokyo National Hospital Department of Pulmonary Medicine

shinjit-tky@umin.ac.jp+81424912111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026